Publications

New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019-22

Health Affairs
Cherla A, Woloshin S, Wagner AK, Wouters OJ, Davis C, Mossialos E, Naci H

Costs of ovarian cancer care since the introduction of poly (ADP-ribose) polymerase inhibitors (PARPis).

Clinical Oncology
Katherine Baumann, Katharine Esselen, Joseph Dottino, Rebecca Costa, Stephanie Argetsinger, Dennis Ross-Degnan, and Anita Katharina Wagner

Communication of uncertainties about recent cancer drugs in large language models

Clinical Oncology
Avi Cherla, Huseyin Naci, Steven Woloshin, Anita Katharina Wagner, and Mei-Sing Ong

Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation.

BMJ Med
Naci H, Shahzad M, Murphy P, Zhang Y, Costa R, Ross JS, Wagner AK.

Ovarian cancer biomarker testing over time in the era of PARP inhibitors

Gynecologic Oncology
Joseph Dottino, Stephanie Argetsinger, Rebecca Costa, Kate Esselen, Dennis Ross-Degnan, Anita Wagner

Patients deserve better information on new drugs.

BMJ
Davis C, Wagner AK, Mintzes B, Scowcroft H, Woloshin S, Naci H

Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer.

Value Health
Dottino JA, Esselen KM, Costa R, Argetsinger S, Shahzad M, Ross-Degnan D, Wagner AK

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.

J Pharm Policy Pract
Shahzad M, Naci H, Esselen KM, Dottino JA, Wagner AK

Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.

Lancet Oncol
Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.

Lancet Reg Health West Pac
Wei Y, Zhang Y, Xu Z, Wang G, Zhou Y, Li H, Shi L, Naci H, Wagner AK, Guan X

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.

BMJ Glob Health
Zhou Y, Naci H, Chen D, Bai L, Shi L, Guan X, Wagner AK

Changing Tides? Anticancer Biologic and Biosimilar Use in Medicare Part B, 2019-2021.

JCO Oncol Pract
McClean AR, Wagner AK, Lu CY

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.

J Glob Health
Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X

Impact of a national antibiotic stewardship intervention in China targeting carbapenem overuse: an interrupted time-series analysis.

Int J Antimicrob Agents
Xu S, Kitchen C, Liu Y, Kabba JA, Hayat K, Wang X, Wang G, Zhang F, Chang J, Fang Y, Wagner AK, Ross-Degnan D

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis.

Lancet Reg Health Am
Ivama-Brummell AM, Marciniuk FL, Wagner AK, Osorio-de-Castro CGS, Vogler S, Mossialos E, Tavares-de-Andrade CL, Naci H

Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.

BMJ
Davis C, Wagner AK, Salcher-Konrad M, Scowcroft H, Mintzes B, Pokorny AMJ, Lew J, Naci H

The Effectiveness of Enhanced Primary Healthcare (EnPHC) interventions on Type 2 diabetes management in Malaysia: Difference-in-differences (DID) analysis.

Prim Care Diabetes
Husin M, Teh XR, Ong SM, Lim YMF, Ang SH, Chan CL, Lim MT, Shanmugam S, Khamis N, Jaafar FSA, Ibrahim NI, Nasir NH, Kusuma D, Wagner AK, Ross-Degnan D, Atun R, Sivasampu S

Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway.

JAMA
Shahzad M, Naci H, Wagner AK

Newly approved cancer drugs in China - innovation and clinical benefit.

Nat Rev Clin Oncol
Zhang Y, Wagner AK, Guan X

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020